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Radiation therapyAbstract Neonatal tumors comprise less than two percent of childhood malignancies. Most are
solid tumors, most common histologies being teratoma and neuroblastoma. We encountered a child
who was detected to have a right arm mass on antenatal sonogram, which was diagnosed to be a
primitive neuroectodermal tumor involving the triceps on ﬁne needle aspiration cytology performed
in the post-natal period. The child was successfully treated with multimodality treatment consisting
of surgery, chemotherapy and radiotherapy. We also discuss brieﬂy the problems associated with
therapy in neonatal period. A review of all cases reported to have congenital Ewing’s sarcoma
family of tumors is presented. Novel therapies are needed to improve efﬁcacy and decrease the
devastating side effects of treatment in this age group.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Ewing’s sarcoma family of tumors (ESFTs) is a group of
tumors of neural crest origin, consisting of Ewing’s sarcoma
(ES), Askin’s tumors, and peripheral primitive neuroectoder-
mal tumors (pPNETs) [1]. Mean age at diagnosis is 15 years.
With current multimodality regimens, ﬁve-year survival is
70% [2].
Neonatal presentation is rare, with 35 cases reported in the
literature. We report an antenatally detected pPNET of
triceps, successfully treated with multimodality therapy.Case summary
A 13-month child presented to our department with a congen-
ital right arm swelling. An antenatal maternal abdominal
ultrasound (USG) at 37 weeks of gestation had shown a single
live intrauterine fetus with no structural defects other than a
27 mm cystic subcutaneous right arm swelling (Fig. 1a and
b). He was delivered at term by Caesarian section for meco-
nium stained liquor. No other congenital defects were noted.
The child’s developmental milestones were normal.
At one month, a 5 · 5 cm non-tender, cystic, freely mobile
swelling was noted posterior to the right elbow, with warm
but uninvolved skin and dilated superﬁcial veins. No enlarged
lymph nodes were noted. Doppler USG showed a hyperechoic
mass with vascular periphery, and normal underlying bone and
Figure 1 Antenatal ultrasonogram at 37 weeks’ gestation showing (a) a single live intrauterine fetus with cephalic presentation,
longitudinal lie and ﬂexion attitude. A cystic swelling is seen arising from right arm, (b) the size of the arm swelling measures
2.80 · 2.85 cm.
Figure 2 Photomicrographs showing a cellular tumor with rich vascularity (a) H&E ·40. Higher-power view showing predominant
round cells with perivascular arrangement (b) H&E ·200. The tumor cells have scant cytoplasm, hyperchromatic nucleus without
nucleolus and brisk mitotic activity (c) H&E ·400. Immunohistochemical staining for CD99 (MIC-2) demonstrates strong diffuse
membranous positivity in the tumor cells (d) ·400.
220 S. Goyal et al.brachial artery. Fine needle aspiration cytology suggested
malignant round cell tumor. The tumor was excised with clearresection margins. Intraoperatively, the mass was adherent to
triceps and cut section showed hemorrhage and necrosis.
Table 1 Cases of congenital pPNET reported in world literature.
S.No. Author Diagnosis Site Size Mets Surgery Chemotherapy Radiotherapy Follow up Overall survival
1 Angervall [3] pPNET Paravertebral (D10) 6 cm NA None None None Lost to follow up NA
2 Das L, Med Pediatr Oncol 1982 [5] pPNET Left chest wall 16 cm Skin nodules GTE VCR+ Cyclo A/W 9 Gy/8#, 6 MeV Progressive disease, brain
mets
3 months,
11 days (died)
3 Naidu MR, Indian J Pediatr 1989 [6] ES Frontonasal region 8 cm None GTE None Postop RT CR 1 year (NED)
4 Hachitanda Y, Arch Pathol Lab Med 1990 [7] pPNET Rt temporal region 4.5 cm Cervical LNs Excision 1 Cycle VCR +
Cyclo F/B CDDP
Focal RT 22.5 Gy Progressive ds, local
recurrence and CSF mets at
4 months post-op
11 months
5 Lim TC, Head Neck 1994 [8] pPNET Face Small eyelid tumor,
grew to 20 cm
None Debulking
Cyclo + VCR+ Epi +Mtx + CDDP None Progressive ds 10 months (died)
6 Paley C, J Pediatr Hematol Oncol 1996 [9] pPNET Multiple cutaneous
nodules
Few mm to 3–4 cm None None None None Self-resolving, absent at
3 months
16 months (NED)
7 Erdmann D, J Hand Surg 1996 [10] pPNET hand 4 cm None Resection VAC/IE · 12 cycles None CR 4 years (NED)
8 Kaneko, Genes Chromosomes Cancer 1996 [11] pPNET Cheek 9 cm None Partial resection
Carbo + cyclo + Pirarubicin + CDDP+ Eto None CR– > Progressive ds
(bone marrow, pelvis, liver
mets)
2 years (died)
9 Daw JL, J Hand Surg 1997 [12] pPNET Hand 4 cm Yes (thigh and
scalp mets)
Below elbow amputation,
WLE thigh lesion
VAC None Progressive ds (periorbital
and brain mets)
15 months (died)
10 Hsieh HY, Br J Radiol 1998 [13] ES Right humeral diaphysis 16 cm None Shoulder disarticulation None none Soft tissue mets right thigh,
left inguinal region
2 years (on FU)
11 Smith LM, Med Pediatr Oncol 1998 [14] pPNET Paraspinal (L2) 6 cm Lung mets Resection Induction chemo, PSCT Focal RT CR– > recurrence at 8 years 8 years (died)
12 Wang JW, Acta Orthop Scand 1999 [15] ES Right humerus, ST extn+ 10 cm None Refused initially, shoulder
disarticulation for palliation
None None › Size, lung and liver mets 1.5 years (died)
13 Lee, Med Pediatr Oncol 2000 [16] pPNET Sacrococcygeal region >5 cm None Debulking No None Progressive ds (brain mets) 3 months (died)
14 Sebire NJ, Pediatr Dev Pathol 2002 [16] pPNET S/C masses, upper back NA NA Yes (details NA) IVAD None CR Alive
15 Sebire NJ, Pediatr Dev Pathol 2002 [17] pPNET Forearm NA NA none none Palliative RT Progressive ds 1 week (died)
16 Sebire NJ, Pediatr Dev Pathol 2002 [17] pPNET Neck NA NA none IVAD none Progressive ds 6 months (died)
17 Sebire NJ, Pediatr Dev Pathol 2002 [17] pPNET Sacrum NA NA Yes (details NA) VCR+ AMD none Progressive ds 3 months (died)
18 Sebire NJ, Pediatr Dev Pathol 2002 [17] pPNET S/C masses, upper back NA NA Yes (details NA) IVAD None CR Alive
19 Sebire NJ, Pediatr Dev Pathol 2002 [17] PNET Knee NA NA None None None Progressive ds 1 month (died)
20 Sebire NJ, Pediatr Dev Pathol 2002 [17] pPNET Neck NA NA Yes (details NA) IVAD No CR Alive
21 Sebire NJ, Pediatr Dev Pathol 2002 [17] pPNET Axilla NA No IVAD No Progressive ds 1.5 years (died)
22 El Hayek M, J Pediatr Hematol Oncol 2004 [18] pPNET Left hand 3.8 cm No None VAC/IE · 4ﬁ
Cyclo + Topo · 2
None Progressive ds, skeleton,
lungs, liver, and brain mets
2.5 years (died)
23 Carvalho, Int J Pediatr Otorhinolaryngol 2006
[19]
PNET Maxilla 4 cm No Partial resection VCR+ AMD (MMT95
protocol); Cyclo + Adria;
Carbo + Eto
No Progressive ds (local) 2 months (died)
24 Meazza C, J Pediatr Hematol Oncol 2008 [20] pPNET Abdomen NA Abdominal wall,
liver
None VCR+ AMD 2 cycles None Progressive ds, peritoneal,
lung, neck nodes
25 days (died)
25 Saito, Pediatr Blood Cancer 2008 [21] ES Retroperitoneum 6 cm Brain, eye, spinal
canal
None VCR+ Cyclo weekly
followed by
VCR+ Cyclo + Eto + Adria: 7 cycles 70.5 Gy
to brain
lesion,
33 Gy to
retroperitoneum Progressive ds 2 years
10 months (died)
26 Rosa, Pediatr Blood Cancer 2009 [22] pPNET Neck 13 cm None None None None Perinatal death Died at 14 h
after birth
27 Ban, J Clin Neurosci 2010 [23] pPNET Paraspinal soft tissue 8 cm None T11-L1 laminectomy
VCR+ Adria + Eto + CDDP High dose – 9
cycles followed by stem cell transplant
None CR 17 months (NED)
28 Atla, Indian J Pathol Microbiol 2011 [24] ES Chest wall 16 cm None None None None Perinatal death Died within
2 min of birth
29 Krenova, Am J Dermatopathol 2011 [25] pPNET Retroperitoneum 6 cm Liver, lungs,
mediastinum,
bones, brain,
cerebrospinal
meninges
None Cyclo–Topotecan (COG
protocol for high risk
neuroblastoma)
None Progressive ds 4 months (died)
30 Kella, J Coll Physicians Surg Pak 2011 [26] ES Scapular region 7 cm None Gross excision VCR-Adria None Progressive ds with neck
nodes
1 month (died)
31 Crocoli, J Pediatr Surg 2012 [27] pPNET Chest wall 15 cm Bone Gross excision VAC-ICE None CR 54 months
(NED)
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222 S. Goyal et al.Histopathology revealed a well-encapsulated, globular mass
(5.5 · 4 · 3 cm), closest margin being one centimeter. Immuno-
histochemistry showed MIC-2 positivity, and synaptophysin
and leukocyte common antigen negativity. Overall features
suggested pPNET of the right arm (Fig. 2a–d). Staging
workup ruled out systemic metastases. Postoperative MRI
did not show any tumor residuum or axillary nodes.
He received 36 weeks of chemotherapy according to Pediat-
ric Oncology Group/Children’s Cancer Group (POG/CCG)
protocol (VAC/IE), followed by adjuvant 3-D conformal
tumor bed irradiation (6 MV photons, 45 Gray in 25
fractions), with no grade 3 or 4 morbidity. At seven years,
he is disease-free, but has a comparative longitudinal limb
shortening of two centimeters.
Discussion
Neonatal tumors comprise less than two percent of childhood
malignancies, commonest histologies being teratoma and neu-
roblastoma. A high degree of genetic or syndromic association
exists, although infections, maternal drug use and intrauterine
ionizing radiation exposure may be responsible [3].
ESFTs are characterized by uniform, densely packed, small
round cells with round nucleoli-free nuclei and indistinct cyto-
plasm. They express immunohistochemical (MIC-2 gene) and
genetic markers (t(11;22) and t(21;22) translocations), as well
as a novel fusion protein EWS-FLI1, suggesting neural crest
origin [1]. Congenital ESFT is a rare entity. Angervall and
Enzinger described 39 soft tissue tumors indistinguishable
from ES of bone including one case of a 20-month boy with
a congenital paravertebral mass [4]. The child did not receive
any treatment and was lost to follow up. Treatment details
in a congenital chest wall PNET were ﬁrst described by Das
et al. in 1982. Despite surgery, chemotherapy and radiother-
apy, the child died of progressive disease after three months
[5]. Other similar cases including ES or pPNET are mentioned
in Table 1 [4–31]. Eleven of these patients achieved complete
remission, seven following multimodality treatment, and one
had spontaneous regression of cutaneous nodules [6,9–
12,17,23,27,28].
Maygarden described 19 patients under three years with ES
of bone, constituting 2.6% of all evaluable patients (19/734)
registered in the ﬁve Intergroup ES Study protocols [32]. The
most prominent differential in this age group is neuroblas-
toma, which can be distinguished by its neuron-speciﬁc eno-
lase, Leu-7 and synaptophysin positivity, as well as N-myc
ampliﬁcation. There was a preponderance of females
(p< 0.001) and a trend toward more proximal long bone,
rib and pelvic tumors. All nineteen patients received chemo-
therapy and eighteen received radiotherapy. Overall survival
(56%) matched with that in older children. Longest survival
duration was 9.9 years. All disease-related deaths occurred
within four years from diagnosis. Most prominent late morbid-
ities in long-term survivors included post-radiation limb short-
ening in four children and adriamycin-related cardiotoxicity
leading to cerebrovascular accident in one child.
In a recent NIH review, authors discuss various pertinent
issues regarding congenital ESFT, namely, the truth to
existence of such an entity, translocation-negative tumors,
treatment options and outcome [33]. They quote three patients
with round cell tumors initially misdiagnosed as other entities
but later conﬁrmed to have ESFT on molecular and immuno-
Congenital PNET 223histochemical studies. They also mention, on the basis of a ret-
rospective evaluation of 76 tumor samples, that characteristic
translocations may occasionally be absent, either due to inad-
equate tissue, inadequate processing or, sometimes, existence
of rare translocations that may be demonstrable only with
nested RT-PCR or break-apart FISH analysis of EWS gene.
They suggest that conﬁrmatory analysis may not be warranted
in diagnosis that is clear on histology and IHC. The clinical
course in the retrospective evaluation of 21 cases described
by the authors, however, was variable and did not appear to
depend on the kind of translocations. The authors describe
eight cases reported by Sebire et al., which have been assimi-
lated in the current report as well; however three of these were
diagnosed between three months and one year of age, and it is
unclear if these were truly congenital.
European Soft Tissue Sarcoma Group recommends avoid-
ing ifosfamide in children younger than a month and anthracy-
clines in those under three months. Immature organs, delayed
chemotherapy clearance and possibility of long-term treatment
effects are valid concerns, but reports show that these children
tolerate VAC-based therapy well. In a retrospective evaluation
of bone sarcomas treated on various POG/CCG protocols
(1976–2005), only nine out of 1156 patients developed solid
second malignancies at a median follow-up of 6.1 years. All
nine patients had received cyclophosphamide, etoposide and
radiation. Since one-third patients die from disease, relapse
prevention still remains the major goal of therapy [34]. Treat-
ment protocols incorporating novel chemotherapeutic and
molecular agents, sophisticated surgical techniques and efforts
to minimize radiation dose and volumes may help reﬁne
existing measures to enable these children attain a healthy
and productive adulthood.
To our knowledge, this is the ﬁrst case of an antenatally
diagnosed congenital PNET treated successfully with current
ESFT protocol, establishing its safety even in younger chil-
dren. The long-term adverse effects need to be borne in mind
while planning therapy, but not at the cost of compromised
survival.Conﬂict of interest
We have no conﬂict of interest to declare.References
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